

Press Release March 9, 2008

Medical Prognosis Institute (MPI)

Important Solidification of World-Class Core Competency – Gene Expression Analysis w/DNA Microarrays – MPI opens Unrivalled Core Technology to Medicon Valley Drug Discovery Companies:

Medical Prognosis Institute, headquartered in Hørsholm, Denmark, is expanding and strengthening their world-class technology core competency with two new key employees. Jesper Dahlgaard, Ph.D. with eight years' experience working with human DNA microarrays and clinical trials will as a Senior Scientist manage MPI's clinical trials as well as research collaborations and research contracts. Wiktor Mazin, with his Ph.D. focus on classification algorithms for gene expression data will be MPI's new Head of Bioinformatics. Wiktor Mazin has experience from biotech industry and a business degree (HD) from CBS. Both new MPI-management team members will be reporting to Dr. Steen Knudsen, CSO.

The new hires will enable MPI to strengthen and advance its core technological competencies and accelerate time to market of its own proprietary DNA-microarray based products targeted at individual cancer prognosis and individual prediction of anti-cancer treatment response. MPI currently has two products in phase III clinical trials.

DNA Microarray Services – broadly available to Medicon Valley Companies

For the benefit of the biotech industry and academia, MPI's cutting edge technology is now also being made broadly available at highly competitive prices as a service to the biopharmaceutical industry. This service is being offered to biopharmaceutical companies targeting a broad array of diseases where superior quality gene expression analysis is an important tool in making the drug discovery process more effective and informative.

Building on MPI's existing and satisfaction guaranteed customer base (see www.medical-prognosis.com), MPI's unrivalled competency, speed and superior quality, is being made available to all Medicon Valley biopharmaceutical companies and also as a valuable contribution to the general spirit of advancing general competitiveness within the Medicon Valley Alliance group of companies.

MPI has a strong record of performing world-class DNA microarray analysis of mouse and human samples for numerous research projects, and is currently developing drug response predictors for biopharmaceutical companies.

For Medicon Valley companies seeking additional information, kindly contact

Steen Knudsen, Ph.D., CSO or Jesper Drejet, MBA, CEO @

Medical Prognosis Institute A/S
7 Agern Alle
DK-2970 Hørsholm
Denmark
Phone: +45-45811926
Or +45-40862156
Email: jd@medical-prognosis.com
steen@medical-prognosis.com

or visit our website:

www.medical-prognosis.com